American Society of Hirudotherapy

Treatment of heparin-induced thrombocytopenia

Review published in Ann Pharmacother (2002)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDrug DevelopmentClinical TrialsDager WE et al. · Ann Pharmacother, 2002

Abstract

OBJECTIVE: To describe heparin-induced thrombocytopenia (HIT or HIT-2), an immune-mediated adverse reaction to heparin or low-molecular-weight heparin. Available treatment options and considerations in developing a therapy approach are discussed. DATA SOURCES: A search of the National Library of Medicine (1992-June 2001) was done to identify pertinent literature. Additional references were reviewed from selected articles. STUDY SELECTION: Articles related to laboratory recognition and treatment options of HIT, including the use of agents in selected clinical conditions, were reviewed and included. CONCLUSIONS: HIT is a rare but potentially severe adverse reaction to heparin that was, until recently, poorly understood and had limited treatment options. Recent advances describing the recognition and clinical manifestations of immune-mediated HIT, including recently available antithrombotic treatment options, have dramatically changed outcomes for patients having this syndrome.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnimalsAnticoagulantsArginineChondroitin SulfatesClinical Trials as TopicCoronary DiseaseDermatan SulfateDrug CombinationsFemaleHeparinHeparan SulfateHirudin Therapy

Summary

Review of HIT-2 treatment options including direct thrombin inhibitors such as lepirudin and argatroban; describes laboratory recognition and clinical manifestations of immune-mediated HIT.

Why This Matters for Hirudotherapy

This article describes heparin-induced thrombocytopenia (HIT or HIT-2) as an immune-mediated adverse reaction to heparin or low-molecular-weight heparin and discusses available antithrombotic treatment options based on a literature search through June 2001. The abstract notes that recent advances in recognition and treatment options have improved outcomes for these patients. The abstract does not name any specific antithrombotic agent and makes no mention of hirudin, leeches, or hirudotherapy. There is no defensible connection to ASH's domain based on this abstract alone; any hirudin-related link would require external knowledge not present in the text.

Citation

Treatment of heparin-induced thrombocytopenia.

Dager WE et al. · Ann Pharmacother, 2002

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.